<DOC>
	<DOCNO>NCT00674791</DOCNO>
	<brief_summary>This study evaluate safety feasibility administer peptide vaccine consist twelve different tumor-rejection antigen patient high risk ( TxN2-3M0 ) metastatic breast cancer evidence disease follow completion systemic therapy . The vaccine design elicit immune response twelve different pathway essential tumor growth , survival metastasis .</brief_summary>
	<brief_title>Study Cancer Peptides Vaccine Plus GM-CSF Adjuvant Treatment High Risk ( TXN2-3M0 ) Metastatic Breast Cancer With No Evidence Disease</brief_title>
	<detailed_description>The primary endpoint determine safety feasibility administer cancer peptide patient high risk ( TxN2-3M0 ) metastatic breast cancer evidence disease follow completion systemic therapy , secondary objective evaluate immune response disease relapse survival . Two cohort 9 patient treat different dos vaccine . They receive peptide vaccine subcutaneously week 0,1,2,4,5 , 6 receive immunization every 1 month 6 month disease recurrence . Toxicity assess dose level use CTCv3 toxicity criterion .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HLAA2 patient histologically confirm , TxN23M0 metastatic breast cancer evidence disease complete adjuvant systemic chemotherapy trastuzumab Subjects treat 4 week prior chemotherapy , radiation therapy immunotherapy , may receive hormonal therapy History autoimmune disease Serious intercurrent chronic acute illness Active hepatitis Serologic evidence HIV , splenectomy Receiving steroid immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Immunotherapeutic vaccine</keyword>
	<keyword>breast cancer</keyword>
	<keyword>TxN2-3M0 breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>antigen</keyword>
	<keyword>Histologically confirm , TxN2-3M0 metastatic breast cancer</keyword>
</DOC>